Current role of myeloperoxidase in routine clinical practice

References

• Duseja R, Feldman JA. Missed acute cardiac ischemia in the ED: limitations of diagnostic testing. Am. J. Emerg. Med.22, 219–225 (2004).
   PubMed Web of Science ®Google Scholar
• Pope JH, Aufderheide TP, Ruthazer R et al. Missed diagnoses of acute cardiac ischemia in the emergency department. N. Engl. J. Med.342, 1163–1170 (2000).
   PubMed Web of Science ®Google Scholar
• Bertrand ME, Simoons ML, Fox KA et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur. Heart J.23, 1809–1840 (2002).
   PubMed Web of Science ®Google Scholar
• Panteghini M, Apple FS, Christenson RH et al. Proposals from IFCC Committee on Standardization of Markers of Cardiac Damage (C-SMCD): recommendations on use of biochemical markers of cardiac damage in acute coronary syndromes. Scand. J. Clin. Lab. Invest. Suppl.230, 103–112 (1999).
   PubMedGoogle Scholar
• Wu AH, Apple FS, Gibler WB, Jesse RL, Warshaw MM, Valdes R Jr. National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for the use of cardiac markers in coronary artery diseases. Clin. Chem.45, 1104–1121 (1999).
   PubMed Web of Science ®Google Scholar
• Apple FS, Wu AH, Mair J et al. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin. Chem.51, 810–824 (2005).
   PubMed Web of Science ®Google Scholar
• Ross R. Atherosclerosis: an inflammatory disease. N. Engl. J. Med.340, 115–126 (1999).
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Hazen SL. Myeloperoxidase and cardiovascular disease. Arterioscler. Thromb. Vasc. Biol.25, 1102–1111 (2005).
   PubMed Web of Science ®Google Scholar
• Loria V, Dato I, Graziani F, Biasucci LM. Myeloperoxidase: a new biomarker of inflammation in ischemic heart disease and acute coronary syndromes. Mediators Inflamm.2008, 135625 (2008).
   PubMed Web of Science ®Google Scholar
• Zhang R, Brennan ML, Fu X et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA286, 2136–2142 (2001).
   PubMed Web of Science ®Google Scholar
• Hazen SL, Heinecke JW. 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J. Clin. Invest.99, 2075–2081 (1997).
   PubMed Web of Science ®Google Scholar
• Thukkani AK, McHowat J, Hsu FF, Brennan ML, Hazen SL, Ford DA. Identification of α-chloro fatty aldehydes and unsaturated lysophosphatidylcholine molecular species in human atherosclerotic lesions. Circulation108, 3128–3133 (2003).
   PubMed Web of Science ®Google Scholar
• Sugiyama S, Okada Y, Sukhova GK, Virmani R, Heinecke JW, Libby P. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am. J. Pathol.158, 879–891 (2001).
   PubMed Web of Science ®Google Scholar
• Hazell LJ, Baernthaler G, Stocker R. Correlation between intima-to-media ratio, apolipoprotein B-100, myeloperoxidase, and hypochlorite-oxidized proteins in human atherosclerosis. Free Radic. Biol. Med.31, 1254–1262 (2001).
   PubMed Web of Science ®Google Scholar
• Naruko T, Ueda M, Haze K et al. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation106, 2894–2900 (2002).
   PubMed Web of Science ®Google Scholar
• de Servi S, Mazzone A, Ricevuti G et al. Expression of neutrophil and monocyte CD11B/CD18 adhesion molecules at different sites of the coronary tree in unstable angina pectoris. Am. J. Cardiol.78, 564–568 (1996).
   PubMed Web of Science ®Google Scholar
• Buffon A, Biasucci LM, Liuzzo G, D’Onofrio G, Crea F, Maseri A. Widespread coronary inflammation in unstable angina. N. Engl. J. Med.347, 5–12 (2002).
   PubMed Web of Science ®Google Scholar
• Bombeli T, Schwartz BR, Harlan JM. Endothelial cells undergoing apoptosis become proadhesive for nonactivated platelets. Blood93, 3831–3838 (1999).
   PubMed Web of Science ®Google Scholar
• Landmesser U, Hornig B, Drexler H. Endothelial function: a critical determinant in atherosclerosis? Circulation109, II27–II33 (2004).
   PubMed Web of Science ®Google Scholar
• Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J. Clin. Invest.100, 2153–2157 (1997).
   PubMed Web of Science ®Google Scholar
• Forgione MA, Leopold JA, Loscalzo J. Roles of endothelial dysfunction in coronary artery disease. Curr. Opin. Cardiol.15, 409–415 (2000).
   PubMed Web of Science ®Google Scholar
• Celermajer DS, Sorensen KE, Bull C, Robinson J, Deanfield JE. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J. Am. Coll. Cardiol.24, 1468–1474 (1994).
   PubMed Web of Science ®Google Scholar
• Ludmer PL, Selwyn AP, Shook TL et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N. Engl. J. Med.315, 1046–1051 (1986).
   PubMed Web of Science ®Google Scholar
• Zhang C, Reiter C, Eiserich JP et al.L-arginine chlorination products inhibit endothelial nitric oxide production. J. Biol. Chem.276, 27159–27165 (2001).
   PubMed Web of Science ®Google Scholar
• Zhang C, Patel R, Eiserich JP et al. Endothelial dysfunction is induced by proinflammatory oxidant hypochlorous acid. Am. J. Physiol. Heart Circ. Physiol.281, H1469–H1475 (2001).
   Web of Science ®Google Scholar
• Zou MH, Shi C, Cohen RA. Oxidation of the zinc–thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite. J. Clin. Invest.109, 817–826 (2002).
   PubMed Web of Science ®Google Scholar
• Marsche G, Heller R, Fauler G et al. 2-chlorohexadecanal derived from hypochlorite-modified high-density lipoprotein-associated plasmalogen is a natural inhibitor of endothelial nitric oxide biosynthesis. Arterioscler. Thromb. Vasc. Biol.24, 2302–2306 (2004).
   PubMed Web of Science ®Google Scholar
• Eiserich JP, Baldus S, Brennan ML et al. Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science296, 2391–2394 (2002).
   PubMed Web of Science ®Google Scholar
• Vita JA, Brennan ML, Gokce N et al. Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation110, 1134–1139 (2004).
   PubMed Web of Science ®Google Scholar
• Baldus S, Heitzer T, Eiserich JP et al. Myeloperoxidase enhances nitric oxide catabolism during myocardial ischemia and reperfusion. Free Radic. Biol. Med.37, 902–911 (2004).
   PubMed Web of Science ®Google Scholar
• Askari AT, Brennan ML, Zhou X et al. Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction. J. Exp. Med.197, 615–624 (2003).
   PubMed Web of Science ®Google Scholar
• Dominguez-Rodriguez A, Samimi-Fard S, Abreu-Gonzalez P, Garcia-Gonzalez MJ, Kaski JC. Prognostic value of admission myeloperoxidase levels in patients with ST-segment elevation myocardial infarction and cardiogenic shock. Am. J. Cardiol.101, 1537–1540 (2008).
   PubMed Web of Science ®Google Scholar
• Schindhelm RK, van der Zwan LP, Teerlink T, Scheffer PG. Myeloperoxidase: a useful biomarker for cardiovascular disease risk stratification? Clin. Chem.55, 1462–1470 (2009).
   PubMed Web of Science ®Google Scholar
• Baldus S, Heeschen C, Meinertz T et al. Myeloperoxidase serum levels predicts risk in patients with acute coronary syndromes. Circulation108, 1440–1445 (2003).
   PubMed Web of Science ®Google Scholar
• Mocatta TJ, Pilbrow AP, Cameron VA et al. Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction. J. Am. Coll. Cardiol.49, 1993–2000 (2007).
   PubMed Web of Science ®Google Scholar
• Morrow DA. Appraisal of myeloperoxidase for evaluation of patients with suspected acute coronary syndromes. J. Am. Coll. Cardiol.49, 2001–2002 (2007).
   PubMed Web of Science ®Google Scholar
• Baldus S, Rudolph V, Roiss M et al. Heparins increase endothelial nitric oxide bioavailability by liberating vessel-immobilized myeloperoxidase. Circulation113, 1871–1878 (2006).
   PubMed Web of Science ®Google Scholar
• Shih J, Datwyler SA, Hsu SC et al. Effect of collection tube type and preanalytical handling on myeloperoxidase concentrations. Clin. Chem.54, 1076–1079 (2008).
   PubMed Web of Science ®Google Scholar
• Dominguez-Rodriguez A, Abreu-Gonzalez P, Kaski JC. Diurnal variation of circulating myeloperoxidase levels in patients with ST-segment elevation myocardial infarction. Int. J. Cardiol.144, 407–409 (2010).
   PubMed Web of Science ®Google Scholar
• Meuwese MC, Stroes ES, Hazen SL et al. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J. Am. Coll. Cardiol.50, 159–165 (2007).
   PubMed Web of Science ®Google Scholar
• Ndrepepa G, Braun S, Mehilli J, von Beckerath N, Schömig A, Kastrati A. Myeloperoxidase level in patients with stable coronary artery disease and acute coronary syndromes. Eur. J. Clin. Invest.38, 90–96 (2008).
   PubMed Web of Science ®Google Scholar
• Cavusoglu E, Ruwende C, Eng C et al. Usefulness of baseline plasma myeloperoxidase levels as an independent predictor of myocardial infarction at two years in patients presenting with acute coronary syndrome. Am. J. Cardiol.99, 1364–1368 (2007).
   PubMed Web of Science ®Google Scholar
• Esporcatte R, Rey HC, Rangel FO et al. Predictive value of myeloperoxidase to identify high risk patients admitted to the hospital with acute chest pain. Arq. Bras. Cardiol.89, 377–384 (2007).
   PubMed Web of Science ®Google Scholar
• Morrow DA, Sabatine MS, Brennan ML et al. Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. Eur. Heart J.29, 1096–1102 (2008).
   PubMed Web of Science ®Google Scholar
• Khan SQ, Kelly D, Quinn P, Davies JE, Ng LL. Myeloperoxidase aids prognostication together with N-terminal pro-B-type natriuretic peptide in high-risk patients with acute ST elevation myocardial infarction. Heart93, 826–831 (2007).
   PubMed Web of Science ®Google Scholar
• Brennan ML, Penn MS, Van Lente F et al. Prognostic value of myeloperoxidase in patients with chest pain. N. Engl. J. Med.349, 1595–1604 (2003).
   PubMed Web of Science ®Google Scholar
• Tang WH, Wu Y, Nicholls SJ, Hazen SL. Plasma myeloperoxidase predicts incident cardiovascular risks in stable patients undergoing medical management for coronary artery disease. Clin. Chem.57(1), 33–39 (2011).
   PubMed Web of Science ®Google Scholar
• Apple FS, Smith SW, Pearce LA, Murakami MM. Assessment of the multiple-biomarker approach for diagnosis of myocardial infarction in patients presenting with symptoms suggestive of acute coronary syndrome. Clin. Chem.55, 93–100 (2009).
   PubMed Web of Science ®Google Scholar
• Stefanescu A, Braun S, Ndrepepa G et al. Prognostic value of plasma myeloperoxidase concentration in patients with stable coronary artery disease. Am. Heart J.155, 356–360 (2008).
   PubMed Web of Science ®Google Scholar
• Kubala L, Lu G, Baldus S, Berglund L, Eiserich JP. Plasma levels of myeloperoxidase are not elevated in patients with stable coronary artery disease. Clin. Chim. Acta.394, 59–62 (2008).
   PubMed Web of Science ®Google Scholar
• McCann CJ, Glover BM, Menown IB et al. Prognostic value of a multimarker approach for patients presenting to hospital with acute chest pain. Am. J. Cardiol.103, 22–28 (2009).
   PubMed Web of Science ®Google Scholar
• Eggers KM, Dellborg M, Johnston N et al. Myeloperoxidase is not useful for the early assessment of patients with chest pain. Clin. Biochem.43, 240–245 (2010).
   PubMed Web of Science ®Google Scholar
• Hoy A, Trégouët D, Leininger-Muller B et al. Serum myeloperoxidase concentration in a healthy population: biological variations, familial resemblance and new genetic polymorphisms. Eur. J. Hum. Genet.9, 780–786 (2001).
   PubMed Web of Science ®Google Scholar
• Zhou T, Zhou SH, Qi SS et al. The effect of atorvastatin on serum myeloperoxidase and CRP levels in patients with acute coronary syndrome. Clin. Chim. Acta368, 168–172 (2006).
   PubMed Web of Science ®Google Scholar
• Ndrepepa G, Braun S, Schömig, Kastrati A. Impact of therapy with statins, β-blockers and angiotensin-converting enzyme inhibitors on plasma myeloperoxidase in patients with coronary artery disease. Clin. Res. Cardiol. DOI: 10.1007/s00392-010-0247-2 (2010) (Epub ahead of print).
   Google Scholar
• Andreou I, Tousoulis D, Miliou A et al. Effects of rosuvastatin on myeloperoxidase levels in patients with chronic heart failure: a randomized placebo-controlled study. Atherosclerosis210, 194–198 (2010).
   PubMed Web of Science ®Google Scholar
• Morrow DA, de Lemos JA. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation115, 949–952 (2007).
   PubMed Web of Science ®Google Scholar
• Libby P, Ridker PM, Hansson GK; Leducq Transatlantic Network on Atherothrombosis. Inflammation in atherosclerosis: from pathophysiology to practice. J. Am. Coll. Cardiol.54, 2129–2138 (2009).
   PubMed Web of Science ®Google Scholar
• Wong ND, Gransar H, Narula J et al. Myeloperoxidase, subclinical atherosclerosis, and cardiovascular disease events. JACC Cardiovasc. Imaging2, 1093–1099 (2009).
   PubMed Web of Science ®Google Scholar